FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Toyoki Mori

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Drug Dose Response Relationship

Disorders

Procedures

Physiology

Hemodynamics

Co-author Network

Publications

TOP 3
Toshiki Miyazaki; Hiroyuki Fujiki; Yoshitaka Yamamura; Shigeki Nakamura; Toyoki Mori
Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Ayako Hashimoto; Goro Miyakoda; Yoshimi Hirose; Toyoki Mori
Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism.
Shiro Tochizawa; Masahiro Muraguchi; Yasukazu Ohmoto; Keiko Oga; Toyoki Mori
Functional expression of human type I interferon receptors in the mouse liver.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Toyoki Mori (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Toshiki Miyazaki; Hiroyuki Fujiki; Yoshitaka Yamamura; Shigeki Nakamura; Toyoki Mori
Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Cardiovascular drug reviews 2007;25(1):1-13.
2006: Ayako Hashimoto; Goro Miyakoda; Yoshimi Hirose; Toyoki Mori
Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism.
Atherosclerosis 2006;189(2):350-7.
2006: Shiro Tochizawa; Masahiro Muraguchi; Yasukazu Ohmoto; Keiko Oga; Toyoki Mori
Functional expression of human type I interferon receptors in the mouse liver.
Biochemical and biophysical research communications 2006;346(1):61-6.
2006: Toyoki Mori; Ayako Hashimoto
Direct positive chronotropic action by angiotensin II in the isolated mouse atrium.
Life sciences 2006;79(7):637-40.
2006: Shuji Itoh; Sakiko Yamada; Toyoki Mori; Takashi Miwa; Katsura Tottori; Yasufumi Uwahodo; Yoshitaka Yamamura; Meiko Fukuda; Koji Yamamoto; Akito Tanoue; Gozoh Tsujimoto
Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor.
American journal of physiology. Endocrinology and metabolism 2006;291(1):E147-51.
2006: Shiro Tochizawa; Yasukazu Ohmoto; Toyoki Mori
A novel modification of a flow cytometric assay of phosphorylated STAT1 in whole blood lymphocytes for rapid detection of interferon-alpha signal in vivo.
Journal of immunological methods 2006;313(1-2):29-37.
2005: Takako Nakashima; Takashi Maeda; Hisashi Nagamoto; Takeshi Kumakura; Masaaki Takai; Toyoki Mori
Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats.
Digestive diseases and sciences 2005;50 Suppl 1():S124-31.
2005: Toshiki Miyazaki; Yoshitaka Yamamura; Toshiyuki Onogawa; Shigeki Nakamura; Shizuo Kinoshita; Sunao Nakayama; Hiroyuki Fujiki; Toyoki Mori
Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.
Endocrinology 2005;146(7):3037-43.
2005: Yoshihiro Tadori; Takashi Miwa; Katsura Tottori; Kevin D Burris; Arlene Stark; Toyoki Mori; Tetsuro Kikuchi
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
European journal of pharmacology 2005;515(1-3):10-9.
2005: Katsumi Ikezono; Masayuki Kamata; Toyoki Mori
Adrenal influences on the inhibitory effects of procaterol, a selective Beta-two-adrenoceptor agonist, on antigen-induced airway microvascular leakage and bronchoconstriction in Guinea pigs.
Pharmacology 2005;73(4):209-15.
2004: Hideki Ito; Goro Miyakoda; Toyoki Mori
Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Platelets 2004;15(5):293-301.
2004: Shiro Tochizawa; Seiji Akamatsu; Yoshihiro Sugiyama; Masahiro Muraguchi; Yasukazu Ohmoto; Yukihisa Ono; Hiroshi Ishikawa; Akira Tanigami; Takumi Sumida; Toyoki Mori
A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets.
Journal of pharmacological and toxicological methods 2004;50(1):59-66.
2004: Shigeki Nakamura; Takahiro Hirano; Toshiyuki Onogawa; Shuji Itoh; Ayako Hashimoto; Yoshitaka Yamamura; Kazumi Kondo; Toyoki Mori; Toshimi Kambe
Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs.
Journal of pharmacological sciences 2004;94(4):426-33.
2004: Toyoki Mori; Ayako Hashimoto; Hiromichi Takase; Toshimi Kambe
Nitric oxide (NO) is not involved in accentuated antagonism for chronotropy in the isolated mouse atrium.
Naunyn-Schmiedeberg's archives of pharmacology 2004;369(4):363-6.
2004: Kensuke Orito; Masami Kishi; Hiroyuki Fujiki; Toru Nakazawa; Takashi Imaizumi; Yukio Kimura; Toyoki Mori; Toshimi Kambe
A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion.
Journal of pharmacological and toxicological methods 2004;49(1):25-9.
2003: Shigeki Nakamura; Takahiro Hirano; Yoshitaka Yamamura; Shuji Itoh; Kazumi Kondo; Toyoki Mori; Toshimi Kambe
Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats.
Journal of pharmacological sciences 2003;93(4):484-8.
2002: Kazumi Kondo; Keizo Kan; Yoshihisa Tanada; Masahiko Bando; Tomoichi Shinohara; Muneaki Kurimura; Hidenori Ogawa; Shigeki Nakamura; Takahiro Hirano; Yoshitaka Yamamura; Masaru Kido; Toyoki Mori; Michiaki Tominaga
Characterization of orally active nonpeptide vasopressin V(2) receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-Chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin- 5-yl]-N-isopropylacetamide.
Journal of medicinal chemistry 2002;45(17):3805-8.
2002: Kensuke Orito; Takashi Imaizumi; Kenji Yoshida; Masami Kishi; Hiroyuki Fujiki; Toyoki Mori
Effect of oral OPC-28326, a selective femoral arterial vasodilator, on hindlimb subcutaneous tissue temperature in conscious dogs under buprenorphine sedation.
Japanese journal of pharmacology 2002;88(1):119-22.
2001: Kensuke Orito; Masami Kishi; Takashi Imaizumi; T Nakazawa; Ayako Hashimoto; Toyoki Mori; Toshimi Kambe
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
British journal of pharmacology 2001;134(4):763-70.
2001: Toyoki Mori; H Takase; K Toide; T Hirano; T Kambe; N Nakayama; A Schwartz
Pranidipine, a 1,4-dihydropyridine calcium channel blocker that enhances nitric oxide-induced vascular relaxation.
Cardiovascular drug reviews 2001;19(1):1-8.
2000: Shigeki Nakamura; Takahiro Hirano; K Tsujimae; M Aoyama; Kazumi Kondo; Yoshitaka Yamamura; Toyoki Mori; Michiaki Tominaga
Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1005-11.
2000: Kazumi Kondo; Hidenori Ogawa; Tomoichi Shinohara; M Kurimura; Yoshihisa Tanada; Keizo Kan; H Yamashita; Shigeki Nakamura; Takahiro Hirano; Yoshitaka Yamamura; Toyoki Mori; Michiaki Tominaga; A Itai
Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
Journal of medicinal chemistry 2000;43(23):4388-97.
2000: T Sogabe; Toyoki Mori; M Ohura; M Tominaga; K Koga; Y Yabuuchi
Venodilatory effect of pranidipine, a calcium channel blocker, monitored with perfluorocarbon in vivo (19)F-NMR spectroscopy.
Magnetic resonance imaging 2000;18(8):1011-6.
2000: Shigeki Nakamura; Yoshitaka Yamamura; S Itoh; Takahiro Hirano; K Tsujimae; M Aoyama; Kazumi Kondo; Hidenori Ogawa; Tomoichi Shinohara; Keizo Kan; Yoshihisa Tanada; S Teramoto; T Sumida; S Nakayama; K Sekiguchi; T Kambe; G Tsujimoto; Toyoki Mori; Michiaki Tominaga
Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
British journal of pharmacology 2000;129(8):1700-6.
2000: Takahiro Hirano; Yoshitaka Yamamura; Shigeki Nakamura; T Onogawa; Toyoki Mori
Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
The Journal of pharmacology and experimental therapeutics 2000;292(1):288-94.
1999: Kensuke Orito; Takashi Imaizumi; Kenji Yoshida; Hiroyuki Fujiki; Masami Kishi; S Teramoto; M Tanaka; H Shimizu; M Tominaga; Y Kimura; J Kambayashi; Toyoki Mori
Mechanisms of action of OPC-28326, a selective hindlimb vasodilator.
The Journal of pharmacology and experimental therapeutics 1999;291(2):604-11.
1999: Kazumi Kondo; Hidenori Ogawa; H Yamashita; H Miyamoto; M Tanaka; K Nakaya; K Kitano; Yoshitaka Yamamura; Shigeki Nakamura; T Onogawa; Toyoki Mori; Michiaki Tominaga
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Bioorganic & medicinal chemistry 1999;7(8):1743-54.
1999: T Hirano; Toyoki Mori; M Kido; K Toide; M Ohura; Hiroyuki Fujiki; Kensuke Orito; Kenji Yoshida; K Ikezono; T Sumida; N Nakayama; Y Yabuuchi
Differential properties of the optical-isomers of pranidipine, a 1,4-dihydropyridine calcium channel modulator.
Fundamental & clinical pharmacology 1999;13(6):650-5.
1998: Yoshitaka Yamamura; Shigeki Nakamura; S Itoh; Takahiro Hirano; T Onogawa; T Yamashita; Y Yamada; K Tsujimae; M Aoyama; K Kotosai; Hidenori Ogawa; H Yamashita; Kazumi Kondo; Michiaki Tominaga; G Tsujimoto; Toyoki Mori
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
The Journal of pharmacology and experimental therapeutics 1998;287(3):860-7.
1998: Toyoki Mori; T Takeuchi; M Ohura; G Miyakoda; Hiroyuki Fujiki; Kensuke Orito; Kenji Yoshida; T Hirano; Y Yamamura; T Sumida; Y Nakaya; H Satake; F Hata
Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta.
Molecular and cellular biochemistry 1998;178(1-2):335-43.
1997: T Hirano; M Ohura; Kensuke Orito; Hiroyuki Fujiki; G Miyakoda; Toyoki Mori
Venodilator effects of pranidipine, a 1,4-dihydropyridine Ca2+ channel antagonist, in rats: comparison with nifedipine and amlodipine.
European journal of pharmacology 1997;324(2-3):201-4.
1997: M Ishikawa; K Koga; Hiroyuki Fujiki; Toyoki Mori; Y Yabuuchi
Comparative study of toborinone (OPC-18790) and milrinone on energy metabolism in microembolized guinea pig hearts.
Life sciences 1997;61(23):2351-8.
1997: T Sogabe; T Imaizumi; Toyoki Mori; M Tominaga; K Koga; Y Yabuuchi
Effects of vasodilators on the signal intensity of perfluorocarbon monitored by in vivo 19F-NMR spectroscopy.
Magnetic resonance imaging 1997;15(3):341-5.
1996: S Itoh; Toyoki Mori; Hiroyuki Fujiki; Michiaki Tominaga
Effects of toborinone on myocardial oxygen consumption in pacing-induced heart failure dogs.
Arzneimittel-Forschung 1996;46(12):1105-9.
1996: Hiroyuki Fujiki; Toyoki Mori; K Yoshida; T Imaizumi; Michiaki Tominaga
OPC-18790, a novel positive inotropic agent, has both arterial and venous vascular dilating actions in the dog.
European journal of pharmacology 1996;313(3):191-200.
1996: Kensuke Orito; H Takase; Hiroyuki Fujiki; Toyoki Mori
Effects of toborinone (OPC-18790), a new positive inotropic agent, on action potential in guinea pig sinoatrial node: compared with milrinone and E-4031.
Japanese journal of pharmacology 1996;72(1):79-82.
1996: Hidenori Ogawa; H Yamashita; Kazumi Kondo; Yoshitaka Yamamura; H Miyamoto; K Kan; K Kitano; M Tanaka; K Nakaya; S Nakamura; Toyoki Mori; Michiaki Tominaga; Y Yabuuchi
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
Journal of medicinal chemistry 1996;39(18):3547-55.
1996: T Fujioka; S Teramoto; S Tsujimi; K Takemoto; Toyoki Mori; T Hosokawa; T Sumida; Michiaki Tominaga; Y Yabuuchi
Synthesis and biological activities of optically active 6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)-quinolinone (OPC-18790).
Chemical & pharmaceutical bulletin 1996;44(8):1596-8.
1996: H Takase; Kensuke Orito; Toyoki Mori; Hiroyuki Fujiki; K Sekiguchi; Michiaki Tominaga; T Iijima
Positive inotropic and chronotropic effects of toborinone and its electrophysiological properties in the isolated hearts of rabbits and guinea-pigs.
Arzneimittel-Forschung 1996;46(6):579-86.
1995: S Itoh; Toyoki Mori; K Yoshida; Hiroyuki Fujiki; Michiaki Tominaga; Y Yabuuchi
Cardiovascular effects of the combination of OPC-18790 and dopamine in halothane-anesthetized dogs.
Japanese journal of pharmacology 1995;69(3):229-37.
1995: M Ishikawa; Toyoki Mori; S Itoh; Hiroyuki Fujiki; K Koga; Michiaki Tominaga; Y Yabuuchi
Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischaemic canine heart: a 31P-MRS study.
Cardiovascular research 1995;30(2):299-306.
1995: T Chihara; Shigeki Nakamura; T Onogawa; T Yamashita; Yoshitaka Yamamura; Toyoki Mori; Michiaki Tominaga; Y Yabuuchi
OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog.
Japanese journal of pharmacology 1995;68(3):345-7.
1995: S Itoh; Toyoki Mori; Michiaki Tominaga; M Ishikawa; K Koga; Y Yabuuchi
Differential effects of OPC-18790, amrinone and dobutamine on cardiac function and energy metabolism in the guinea-pig isolated ischaemic heart.
British journal of pharmacology 1995;114(5):1090-6.
1995: M Chihiro; H Nagamoto; I Takemura; K Kitano; H Komatsu; K Sekiguchi; F Tabusa; Toyoki Mori; Michiaki Tominaga; Y Yabuuchi
Novel thiazole derivatives as inhibitors of superoxide production by human neutrophils: synthesis and structure-activity relationships.
Journal of medicinal chemistry 1995;38(2):353-8.
1994: M Ohura; Toyoki Mori; K Watanabe; K Ikezono; N Nakayama; Michiaki Tominaga; Y Yabuuchi
[Effects of pranidipine (OPC-13340), a novel 1,4-dihydropyridine derivative Ca-antagonist, on isolated porcine coronary contraction and acute myocardial ischemia in the pig].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1994;103(3):101-9.
1994: Y Yamada; Yoshitaka Yamamura; T Chihara; T Onogawa; Shigeki Nakamura; T Yamashita; Toyoki Mori; Michiaki Tominaga; Y Yabuuchi
OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats.
Hypertension 1994;23(2):200-4.
1993: Hidenori Ogawa; Yoshitaka Yamamura; H Miyamoto; Kazumi Kondo; H Yamashita; K Nakaya; T Chihara; Toyoki Mori; Michiaki Tominaga; Y Yabuuchi
Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.
Journal of medicinal chemistry 1993;36(14):2011-7.
1993: Toyoki Mori; N Nakayama; M Ohura; K Ikezono; S Kinoshita; M Kamata; T Hosokawa; S Yamashita; Y Yabuuchi
Cardiovascular effects of OPC-13340, a potent, long-acting 1,4-dihydropyridine calcium channel blocker, in dogs.
Archives internationales de pharmacodynamie et de thérapie 1993;321():41-56.
1992: T Fujioka; S Teramoto; Toyoki Mori; T Hosokawa; T Sumida; Michiaki Tominaga; Y Yabuuchi
Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives.
Journal of medicinal chemistry 1992;35(20):3607-12.
1992: Yoshitaka Yamamura; Hidenori Ogawa; H Yamashita; T Chihara; H Miyamoto; Shigeki Nakamura; T Onogawa; T Yamashita; T Hosokawa; Toyoki Mori
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
British journal of pharmacology 1992;105(4):787-91.
1992: T Hosokawa; Toyoki Mori; Hiroyuki Fujiki; S Kinoshita; K Takemoto; T Imaizumi; T Noda; M Ohura; Michiaki Tominaga; Y Yabuuchi
Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action.
Heart and vessels 1992;7(2):66-75.
1991: Yoshitaka Yamamura; Hidenori Ogawa; T Chihara; Kazumi Kondo; T Onogawa; Shigeki Nakamura; Toyoki Mori; Michiaki Tominaga; Y Yabuuchi
OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.
Science (New York, N.Y.) 1991;252(5005):572-4.
1990: N Nakayama; K Ikezono; Toyoki Mori; S Yamashita; S Nakayama; Y Tanaka; T Hosokawa; Y Minami; K Masutani; Y Yamamura
Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist, in rats.
Journal of cardiovascular pharmacology 1990;15(5):836-44.